Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model
|
|
- Brice Melton
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (1985) 15, Suppl. A, Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model Joyce J. Mordenti, Richard Quintiliani and Charles H. Nightingale Department of Pharmacy Services. Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06115, U.S.A. To determine the effect of the mode of administration on antibiotic efficacy, 300 neutropenic rats were infected intrapcritoneally with an LD-70 inoculum of Pseudomonas aeruginosa and treated with synergistic combinations of amikacin and ticartiliin by intermittent or constant infusion technique. The treatment regimens were designed to provide the same peak serum concentrations that would be obscfted in humans receiving these drugs. Drug administration over the 24-h period was controlled to ensure that intermittent and constant infusion techniques achieved the same area under the serum concentration/time curves. Based on cumulative mortality at 96 h and viable bacterial cell counts at the site of inoculation constant infusion of both antibiotics produced the best therapeutic results. Introduction Of the factors responsible for increasing the cancer patient's susceptibility to infection, neutropenia is the most important; the neutropenic patient is unable to mount an adequate inflammatory response and, hence, must rely almost entirely upon antibiotics to control the infection. The administration schedule of drugs in neutropenic patients may be important in determining whether a patient overcomes infection since Gramnegative bacilli recover rapidly from the effects of /Mactam antibiotics once they are eliminated (Toothaker, Welling & Craig, 1982; Bundtzen et al, 1981; Zinner, Husson & Klastersky, 1981; Bodey, Valdivieso & Yap, 1980; Al-Asadi, Greenwood & O'Grady, 1979; Grasso et al., 1978). Comparative trials relating mode of drug administration to therapeutic efficacy in neutropenic patients have shown that continuous antibiotic infusion usually resulted in eradication of infections even when white blood cell counts remained suppressed (Feld et al., 1977; Bodey et al, 1976; Bodey et al, 1975). Clinical and experimental investigations dealing with this question have been limited, and convincing proof or evidence of the superiority of either mode of administration is lacking (Barza, Kane & Baum, 1983; Gerber et al, 1983; Powell et al, 1983; Klastersky, Thys & Mombelli, 1981; Sande et al, 1981; Feld et al, 1979; Issell et al, 1979; Keating et al, 1979; Bergeron, Nguyen & Gauvreau, 1978). To study further the effect of mode of administration on survival from a bacterial infection, neutropenic rats were infected experimentally with Pseudomonas aeruginosa and treated with synergistic /85/15A S02.00/ The British Society for Antimicrobial Chemotherapy
2 314 J. J. Mordenti et aj. combinations of amikacin and ticarcillin by constant infusion or intermittent dosing schedules. Methods Selection of test organism The strain of Ps. aeruginosa selected for these studies was resistant to amikacin and ticarcillin when used singularly, but sensitive to the combination. This criterion was established to ensure the effects of mode of administration on synergy would be maximized. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBQ of amikacin was 40 and 80 mg/l respectively and the MIC and MBC of ticarcillin was 160 and 320 mg/l respectively. The organism was sensitive to synergistic combinations (i MIC of each drug) of these antibiotics. Neutropenic animal model A neutropenic rat model was selected for the present study for reasons of convenience (cost, size, disposition) and general acceptance by clinical researchers for studies of this nature. Female Sprague-Dawley rats (Taconic Farms, German town, NY 12526) weighing g were used exclusively. The animals were made neutropenic by administering an 80 mg/kg intraperitoneal dose of cyclophosphamide on day 0 and 60 mg/kg on day 4 of the experiment It was previously determined that this dose produced neutropenia for the entire experimental period (Mordenti, 1983). All animals were injected ip with 1 ml of a 5% gastric mucin solution 30 min prior to injecting 3 x 10 8 micro-organisms in the logarithmic growth phase into the peritoneal cavity. These injections took place one day after the second dose of cyclophosphamide (day 5). This procedure resulted in a 70% animal mortality (LD 70 ). The pharmacokinetics of amikacin and ticarcillin were determined in these animals so that the appropriate dose and dosing frequency could be established. The goal was to provide the same peak serum concentrations that would be obtained in humans, i.e. 30 mg/l for amikacin and 200 mg/l for ticarcillin. Cumulative mortality in treatment trials Three-hundred female Sprague-Dawley rats were made neutropenic with ip cyclophosphamide injections on day 0 and day 4. An LD-70 inoculum of Ps. aeruginosa was injected intraperitoneally on day 5. Antibiotic therapy was instituted 4 h after the initiation of infection and continued for 24 h. Drug was administered by intermittent im injection (every 2 h for amikacin and every 3 h for ticarcillin) or by frequent (every 30 min) im injection to simulate constant infusion therapy. All injections were made in the hind legs, and all possible antibiotic combinations were evaluated. Treatment regimens were as follows: amikacin every 2 h (Ab), amikacin every ^ h (approximating to continuous infusion (Ac)), ticarcillin every 3 h (Tb), ticarcillin every \ h (Tc), both drugs bolus dosing (AbTb), both drugs constant infusion (AcTc) and combinations of one drug infused and one bolus dosed (AcTb, AbTc). Each treatment group was comprised of 30 neutropenic rats; the control group was comprised of 60
3 Combination antibiotic therapy 315 neutropenic rats. Animal deaths were recorded every 12 h for 96 h. After 96 h, the white blood cell count began returning to normal. At the end of the study, all surviving rats were sacrificed with a 0-5 ml im dose of euthanasia mixture (35 mg/ml ketamine and 7 mg/ml succinylcholine). As a control procedure, it was previously determined that the administration of ip mucin, ip heat killed Ps. aeruginosa, multiple injections of saline (01 ml im q 3 h for 72 h), injections of amikacin (llmg/kgimq 3h for 72 h), ticarcillin (loomg/kgq 3h for 72 h and amikacin + ticarcillin (given as above) for a ten day period of time did not result in any animal deaths. Bacterial quantitation To investigate the effect of mode of administration on bactericidal potency, an additional 50 rats were rendered neutropenic with cyclophosphamide dnd infected lntraperitoneally with an LD-70 inoculum of Ps. aeruginosa. Forty rats were randomly assigned to the following antibiotic treatment regimens: AbTb, AbTc, AcTb, and AcTc. Ten rats served as controls. Following 24 h of antibiotic therapy, all rats were sacrificed with 0-5 ml of euthanasia mixture. Cardiac blood and peritoneal fluid were removed for microbiological assay. The latter was obtained by exposing the peritoneum, injecting 20 ml of sterile normal saline and 10 ml air, shaking the animal vigorously and withdrawing approximately 20 ml of fluid. Two millilitres of blood were obtained by cardiac puncture. The blood and peritoneal samples were serially diluted in sterile normal saline for enumeration by microbiological plate counts. Statistical evaluation The Chi-square test was used to establish that a statistically significant difference existed in comparisons of differences in proportions. The Chi-square test with Yates' correction was used for pair-wise comparison of differences in proportions. The Fisher's exact test was used for pair-wise comparison of differences in proportions whenever the excepted frequencies for the Chi-square test were less than 5. A P value less than or equal to 0-05 was considered significant (Riegelman, 1981; Colton, 1974). The F test for analysis of variance was used to establish that a statistically significant difference existed in comparisons of differences in geometric means. A P value less than or equal to 0-05 was considered significant. When a statistically significant difference was found, Fischer's least significant difference test for pair-wise comparisons was used to determine which comparisons made contributions to the overall difference. A P value less than or equal to 0-01 was considered significant (Riegelman, 1981; Colton, 1974; Snedecor & Cochran, 1974). Antibiotic pharmacokinetic studies Results When rats were handled in a manner which minimized stress, the in-vivo antibiotic serum profiles for ticarcillin and amikacin could be described by a one compartment open model. Ticarcillin (loomg/kg) produced a peak concentration of mg/1; the serum half-life was approximately 15min. Amikacin (11 mg/kg) produced a peak concentration of mg/1; the serum half-life was approximately 17 mm.
4 316 J. J. Mordenti et al. IOOO Time (mm) Figure 1. Ticarcillin pharmacokinetics in two representative rats after intramuscular injections every 3 h. The curves are theoretical and the points experimental The rodent pharmacokinetic parameters were used to design proper multiple dose administration schedules, i.e., intramuscular injections of amikacin every 2 h (q 2 h) and ticarcillin every 3 h (q 3 h). Constant infusion was approximated by intramuscular injections every half hour (q ^ h). The log of the antibiotic serum concentration was plotted as a function of time for each multiple dosing experiment (Figures 1 to 4). In each trial, the experimental serum concentrations compared favourably with the expected pharmacokinetic curves. Cumulative mortality The results (Figure 5) show that those treatment regimens which had drug infused resulted in higher survival rates the best results were obtained when both drugs were infused. Survival among rats treated with amikacin alone (Ab or Ac) or ticarcillin bolus dosing (Tb) was not significantly different than the survival of control rats. Survival among rats treated with ticarcillin continuous infusion (Tc) or combination drug therapy (AbTb, AbTc, AcTb, and AcTc) was significantly better than controls (P < 0-05 for Tc, and P < 0-01 for combination therapy). Combination drug therapy consisting of continuous infusions of both drugs (AcTc) was significantly better (i ) <O05) than combination therapy in which the ticarcillin was administered intermittently (AbTb or AcTb).
5 Combination antibiotic therapy Time (mm) Fignre 2. Ticarcillin pharmacokinetics in two representative rats after intramuscular injections every $ h. The curves are theoretical and the points experimental Bacterial quantitation The results of quantitative cultures of peritoneal lavage obtained 24 h after challenge with P. aeruginosa are shown in Table I. The bacterial counts correlated with cumulative mortality, and the combination of constant infusion amikacin plus constant infusion ticarcillin was associated with the smallest number of bacteria in the peritoneal cavity. A one-way analysis of variance confirmed a statistical difference in the log colonyforming units (cfu) found in rats in the various treatment groups (P < 0-05). The low number of bacteria found in rats in the AcTc and AcTb treatment groups was responsible for this significant difference. Discussion Presently the most popular therapy for suspected sepsis in neutropenic patients is a combination of an anti-pseudomonas penicillin derivative (e.g., carbenicillin, ticarcillin, mezlocillin, piperacillin) and an anti-pseudomonas aminoglycoside (e.g., gentamicin, tobramycin, amikacin) (Bodey, 1983; KJastersky, 1983). There has been reluctance to employ monotherapy with a /Mactam antibiotic or an aminoglycoside owing to the clinical observation that synergistic combinations against the usual Gram-negative bacteraemic organisms (e.g., Klebsiella, E. coli, Ps. aeruginosa) have been associated with higher survival rates than those obtained with single drug therapy, even against susceptible isolates (Klastersky, Meunier-Carpentier & Prevost, 1977) 400
6 318 J. J. Mordeoti el al Tim* (min) Figure 3. Amikacin pharmacokinetics in two representative rats after intramuscular injections every 2 h The curves are theoretical and the points experimental The mode of antibiotic administration (constant infusion vs. intermittent injection) is currently a subject of debate; for instance, there are several clinical studies in which the continuous infusion of antibiotics appeared to be somewhat more efficacious than that of intermittent dosing in neutropenic patients, yet constant infusion therapy is rarely employed in these patients (Feld, 1977; Valdivieso et al, 1974). The ability of certain organisms to recover quickly from the effects of antibiotics was demonstrated in in-vitro studies when Gram-negative bacteria sensitive to carbenicillin and cephalothin regrew promptly once the antibiotic was depleted (Robinson, 1973). This absence of socalled post-antibiotic effect in the treatment of Gram-negative bacteria with /Mactam antibiotics may have particular clinical relevance in the neutropenic patient owing to their suboptimal natural host defences against bacterial proliferation. As suggested by Keating et al. (1979), for the best clinical outcome in patients with serious defects in host defences, constant inhibitory concentrations of antibiotics may be needed in serum or tissue to protect against the rapid growth of bacteria that might occur if antibiotic levels are absent at these sites for prolonged periods. Although we found in this investigation that the dual bolus dosing schedule produced high peak antibiotic serum concentration for amikacin and ticarcillin, the peaks did not coincide at every dosing interval, producing intervals when only one drug was detectable in the blood and trough concentrations which were low for both drugs. Overall, the time of exposure to the synergistic effect of both antibiotics was
7 Combination antibiotic therapy Tims (min) Figure 4. Amikacin phaimacolunetics in two representative rats after intramuscular injections every \ h. The curves are theoretical and the points experimental 300 Figure 5. Cumulative mortality (per cent) for antibiotic treatment tnals: Ac, amikacin 'continuous infusion' (CI); Ab, amikaan bolus dosing every 2 h (bd); Tc, ticarcilbn CI; Tb, ticarcillin bd every 3 h, AbTb, both drugs bd, AcTc, both drags CI, AbTc, AcTb, combination of bd and CI.
8 320 J. J. Mordenti et al. Table L Efficacy of various dosage regimens of amikacin and ticarcillin based on bacterial recovery in neutropenic rats sacrificed at 24 h Dosage regimen Control AbTb AcTb AbTc AcTc No. of rats positive/ no. tested Peritoneal fluid 10/10' 8/9' 8/9' 8/9' 6/9' Log cfu±sd. ll-4±0-3 59±O76 51 ± ± ±0-ll ' AU control rats died before 24 h. The log cfu represents the bacterial count at the time of death * One rat died before 24 h, and the bacterial count for the rat is not included in the tabulation. The log cfu in treatment rats that died during therapy were as follows AbTb, 8-6; AcTb, 1O4; AbTc, 7-8; AcTc, 6-1. minimal and is probably the cause of the poor response associated with this mode of therapy. Combination therapy consisting of bolus dosing of one drug plus continuous infusion of the second drug was of intermediate success. There were no drug free intervals: one antibiotic was always at J MIC, and the other antibiotic had substantial peaks above \ MIC and troughs well below i MIC. The exposure to the synergistic combination was greater than with the dual bolus dosing schedule but less than with the dual continuous infusion schedule. Intramuscular injections of both antibiotics every { h produced steady-state serum concentrations of ^ MIC for each drug throughout the dosing interval. This concentration represents the 'synergy' MIC for the infecting organism. Although this dosage regimen lacked high peak antibiotic concentrations for each drug, it afforded maximal protection by not allowing prolonged antibiotic-free periods to occur and by achieving the maximal time for a synergistic interaction to occur. In summary, our data indicate that constant infusion of both an aminoglycoside and a penicillin-derivative achieved the best results. When levels were sustained well above the MIC and MBC of the antibiotics for Ps. aeruginosa, which was the situation with constant infusion of antibiotics, animals survived longer and bacteria were eliminated more rapidly. It must be stressed that this is especially true of antibiotic combinations that depend upon the development of synergy in order to eradicate the organism. Intermittent bolus dosing tends to result in non-synergistic drug concentrations for a portion of the dosing interval. The greater the non-synergy the less effective the therapy. Obviously if the organism is exquisitely sensitive to the drug or drug combinations, i.e. has extremely low MIC values, the mode of administration will be relatively unimportant since adequate coverage will result with either mode. Likewise, differences in mode of administration may not be critical in patients with normal host defence mechanisms since organism 'killing' can occur for a period of time after antibiotic concentration fall below the MIC. In neutropenic patients, especially in infections with organisms that have only moderate or poor susceptibility to the drug(s),
9 Combination antibiotic therapy 321 the mode of administration may be important, and the clinician should try to increase the periods of inhibitory drug concentrations by using constant antibiotic administration. Acknowledgements This project was supported by a generous grant from the Combined Hospital Fund, Hartford, CT We wish to thank Al Beroth, Bill Dyckman, Ed Hall, Nancy Reichart, and John Fakas from the Hartford Hospital Animal Research Facility for providing technical assistance and excellent animal care throughout these studies. This work was abstracted from Joyce Mordenti, "Combination antibiotic therapy: Comparison of constant infusion and intermittent bolus dosing in an in-vitro kinetic model and an experimental animal model", Ph.D. dissertation, University of Connecticut, Copies are available through University Microfilm International, 300 N. Zeeb Road, Ann Arbor, MI 48106, U.S.A. References Al-Asadi, M., Greenwood, D. & O'Grady, F. (1979) In vitro model simulating the form of exposure of bacteria to antimicrobial drugs encountered in infection. Antimicrobial Agents and Chemotherapy 16, Barza, M., Kane, A. & Baum, J. (1983). Comparison of the effects of continuous and intermittent systemic administration on the penetration of gentamicin into infected rabbit eyes. Journal of Infectious Diseases 147, Bergeron, M., Nguyen, B & Gauvreau, L. (1978). Influence of constant infusion versus bolus injection of antibiotics on in vivo synergy. Infection, 6, Suppl. I, S38-S46. Bodey, G (1977). Infectious complications in the cancer patient Current Problems in Cancer 1, Bodey, G., Bolivar, V, Fainstein, L. & Jadeja, L. (1983). Infections caused by Pseudomonas aerugutosa. Reviews of Infectious Diseases 5, Bodey, G., Chang, H., Rodriguez, V. & Stewart, D. (1975). Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion. Antimicrobial Agents and Chemotherapy 8, Bodey, G., Rodriguez, V., Valdivieso, M. & Feld, R. (1976). Amikacin for treatment of infections in patients with malignant diseases. Journal of Infectious Diseases 134, Suppl., S241-S427. Bodey, G., Valdivieso, M. & Yap, B. (1980) The role of schedule in antibiotic therapy of the neutropenic patient Infection 8, Suppl. 1, S75-S81. Bundtzen, R., Gerber, A., Cohn, D. & Craig, W (1981) Postantibiotic suppression of bacterial growth. Review of Infectious Diseases 3, Colton, T. (1974). Statistics in Medicine, pp Little, Brown & Co, Boston. Feld, R., Valdivieso, M., Bodey, G. & Rodriguez, V. (1977). A comparative trial of sisomicin therapy by intermittent versus continuous infusion American Journal of Medical Science 11 A, Feld, R., Tuffnell, P. el al. (1979). Empiric therapy for infections in granulocytopenic cancer patients: Continuous infusion of amikacin plus cephalothin. Archives of Internal Medicine 139, 310-^t. Gerber, A., Craig, W. el al. (1983) Impact of dosing intervals on activity of gentamian and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice Journal of Infectious Diseases 147, Grasso, S., Meinardi, G decarneri, I. & Tamassia, V. (1978). New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity Antimicrobial Agents and Chemotherapy 13, 570-6
10 322 J. J. Mordenti et al. Issell, B., Keating, M., Valdivieso, M. & Bodey, G. (1979) Continuous infusion tobramycin combined with carbenicilhn for infections in cancer patients. American Journal of Medical Sciences 277, Keating, M., Bodey, G., Valdivieso, M. & Rodriguez, V. (1979). A randomized comparative trial of three aminoglycosides comparisons of continuous infusions of gentamicin, amikacin, and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine 58, Klastersky, J. (1983). Empiric treatment of infections in neutropenic patients with cancer. Review of Infectious Diseases. Suppl. I. 5, Klastersky, J., Meunier-Carpentier, F. & Prevost, J. (1977). Significance of antimicrobial synergism for the outcome of gram-negative sepsis. American Journal of Medical Science 273, Klastersky, J., Thys, J. & Mombelli, G. (1981). Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria. Review of Infectious Diseases 3, Mordenti, J. (1983). Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an in vitro kinetic model and an experimental animal model. Ph.D. dissertation. University of Connecticut. Powell, S., Thompson, W., Lythe, M. et al. (1983). Once daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases 147, Riegelman, R. (1981). Studying a Study and Testing a Test, pp Little, Brown & Co., Boston. Robinson, G. (1973). Plasma concentrations of penicillin in relation to the antibacterial effect. In Biological Effects of Drugs in Relation to their Concentrations (Davies, D S. & Priehard, B., Eds), pp MacMillan Press, N.Y. Sande, M., Korzeniowski, O. et al. (1981). Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits preliminary observations on the post-antibiotic effect in vivo. Review of Infectious Diseases 3, Snedecor, G. & Cochran, W. (1974). Statistical Methods, 6th Ed., pp Iowa State University Press, Ames, Iowa. Toothaker, R., Welling, P. & Craig, W. (1982). An in vitro model for the study of antibacterial dosage regimen design. Journal of Pharmaceutical Science 71, Valdivieso, M., Feld, R., Rodriguez, V. Bodey, G. (1974). Amikacin therapy of infections in neutropenic patients. American Journal of Medical Science 268, 149 Zinner, S., Husson, M & Klastersky, J (1981). An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. Journal of Infectious Diseases 144, 583-7
Introduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008
Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin
More informationVOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill
VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559 ANTIBIOTIC 6640.* Ill BIOLOGICAL STUDIES WITH ANTIBIOTIC 6640, A NEW BROAD-SPECTRUM AMINOGLYCOSIDE ANTIBIOTIC J. Allan Waitz, Eugene L. Moss, Jr., Edwin
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationExperimental Pseudomonas Bacteremia in Neutropenic Rats
ANTIMICROBIAL AGENTs AND CHZMOTHERAPY, OCt. 1976, p. 646-651 Copyright C) 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. Synergistic Activity of Carbenicillin and Gentamicin in
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationStaphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, OCt. 1981, p. 463-469 0066-4804/81/100463-07$02.00/0 Vol. 20, No. 4 In Vitro and In Vivo Studies of Three Antibiotic Combinations Against Gram-Negative Bacteria and
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationPostantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method
Journal of Antimicrobial Chemotherapy (1988) 22, 23-33 Postantibiotic effect of aminoglycosides on Gram-negative bacteria evaluated by a new method Barforo Isaksson'*, Lennart Nibson*, Rolf Mailer' and
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationJAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationComparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy
Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys Géza Sárközy Department of Pharmacology and Toxicology Faculty of Veterinary Science Szent István University
More informationPatients. Excludes paediatrics, neonates.
Full title of guideline Author Division & Speciality Scope Gentamicin Prescribing Guideline For Adult Patients Annette Clarkson, Specialist Clinical Pharmacist Antimicrobials and Infection Control All
More informationUSA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only
USA Product Label http://www.vetdepot.com PHARMACIA & UPJOHN COMPANY Division of Pfizer Inc. Distributed by PFIZER INC. 235 E. 42ND ST., NEW YORK, NY, 10017 Telephone: 269-833-4000 Fax: 616-833-4077 Customer
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationIN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA
IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of
More informationComparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationThe impact of the pre-treatment interval on antimicrobial efficacy in a biological model
Journal of Antimicrobial Chemotherapy (1993) 31, Suppl. D, 29-39 The impact of the pre-treatment interval on antimicrobial efficacy in a biological model Andreas U. Gerber, Urs Greter, Charlotte Segessemnann
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationIdentification of Factors Affecting In Vivo Aminoglycoside Activity
ANTiMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1992, p. 744-750 0066-4804/92/040744-07$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 4 Identification of Factors Affecting In Vivo
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationUse of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections
SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationPercent Time Above MIC ( T MIC)
8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationPersistent in Kidneys
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1981, p. 381-385 0066-4804/81/030381-05$02.00/0 Vol. 19, No. 3 Prevention of Acute and Chronic Ascending Pyelonephritis in Rats by Aminoglycoside Antibiotics
More informationY. Q. Xiong*, J. Caillon*, X. Y. Zhou*, G. Potel'*, D. Bugnon', P. Le Conte*, F. Le Gallon*, R. Le Floch', D. Baron* and H.
Journal of Antimicrobial Chemotherapy (1995) 35, 697-706 Treatment of experimental rabbit infective endocarditis due to a raultidrug-resistant Pseudomonas aeruginosa with high-dose ceftazidime alone and
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More information.'URRENT THERAPEUTIC RESEA. VOLUME 66, NUMBER 3, MAY/JuNE 2005
.'URRENT THERAPEUTIC RESEA VOLUME 66, NUMBER 3, MAY/JuNE 2005 Efficacy of Moxifloxacin Monotherapy Versus Gatifloxacin Monotherapy, Piperacillin- Tazobactam Combination Therapy, and Clindamycin Plus Gentamicin
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationEach copy of any part of a JSTOR transmission must contain the same copyright notice that appears on the screen or printed page of such transmission.
Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design Author(s): Steven C. Ebert and William A. Craig Source: Infection Control and Hospital Epidemiology,
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationGARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1999, p. 29 34 Vol. 43, No. 1 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Two Pharmacodynamic Models for Assessing
More informationBuilding a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy
Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationAntibiotics have no (or only minimal) effect on human cells and tissues - their action is directed specifically against micro-organisms.
1989 Elsevier Science Publishers B V (Biomedical Division) Dose-response relationships in clinical pharmacology. L Lasagna, S Enll, C.A NaranjOj editors 293 DOSE-RESPONSE RELATIONSHIPS IN ANTIMICROBIAL
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationTOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY. Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya
16 THE JOURNAL OF ANTIBIOTICS JAN. 1972 TOLYPOMYCIN, A NEW ANTIBIOTIC. V IN VITRO AND IN VIVO ANTIMICROBIAL ACTIVITY Masahiro Kondo, Tokiko Oishi and Kanji Tsuchiya Biological Research Laboratories, Research
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationPharmacodynamics of fluoroquinolones. A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box , Wuppertal, Germany
Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. B, 51 59 Pharmacodynamics of fluoroquinolones JAC A. Dalhoff* Bayer AG, Pharma Research Centre, PO Box 101709, 42096 Wuppertal, Germany Fluctuating
More informationReceived 23 December 1996/Returned for modification 27 May 1997/Accepted 24 June 1997
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 1997, p. 1926 1932 Vol. 41, No. 9 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Rationale behind High-Dose Amoxicillin Therapy for
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationExtremely Drug-resistant organisms: Synergy Testing
Extremely Drug-resistant organisms: Synergy Testing Background Acinetobacter baumannii& Pseudomonas aeruginosa Emerging Gram-negative bacilli Part of the ESKAPE group of organisms 1 Enterococcus faecium
More informationPharmacokinetics of gentamicin after iv infusion or iv bolus
Journal of Antimicrobial Chemotherapy (1987) 19, 225-231 Pharmacokinetics of gentamicin after iv infusion or iv bolus F. Meunier", P. Van der Auwera", H. Schmitt*, V. de Maertelaer', and J. Klastersky*
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationComparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal Infections in Monkeys
ANTIbMCROBIAL AGENTS AND CHEMOTHERAPY, June 197, p. 460-465 Copyright 197 American Society for Microbiology Vol. 1, No. 6 Printed in U.S.A. Comparison of Clindamycin, Erythromycin, and Methicillin in Streptococcal
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationEmpiric Treatment of Sepsis. Professor of Clinical Microbiology Department of Microbiology Leicester University U. K.
VOL. 38 NO. 8 CHEMO THERAPY Empiric Treatment of Sepsis Emmerson A M Professor of Clinical Microbiology Department of Microbiology Leicester University U. K. Empiric Treatment of Sepsis The treatment of
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationComparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin Against Gram Negative Aerobic Bacilli
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 18, No. 6 Copyright 1988, Institute for Clinical Science, Inc. Comparison of the Inhibitory and Bactericidal Activity of Aztreonam and Amikacin Against Gram
More informationSpeciality: Therapeutics
Gentamicin Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission May 2017 Date on which
More informationRandomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis
Randomized Controlled Trial on Adjunctive Lavage for Severe Peritoneal Dialysis- Related Peritonitis Steve SM Wong Alice Ho Miu Ling Nethersole Hospital Background PD peritonitis is a major cause of PD
More informationTreatment of peritonitis in patients receiving peritoneal dialysis Antibiotic Guidelines. Contents
Treatment of peritonitis in patients receiving Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Jude Allen (Pharmacist) Additional author(s): Dr David Lewis, Dr Dimitrios Poulikakos,
More information1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 TRADE NAME OF THE MEDICINAL PRODUCT Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2ml contains 20mg of Gentamicin as Gentamicin Sulfate Excipient
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More information